Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company’s existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value. As part of this review process, Oramed will explore potential strategic alternatives that ma(…..) Continue reading »
The Latest Press Releases